<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01751477</url>
  </required_header>
  <id_info>
    <org_study_id>MUV-Neo3</org_study_id>
    <nct_id>NCT01751477</nct_id>
  </id_info>
  <brief_title>Infloran® for Prevention of Necrotizing Enterocolitis</brief_title>
  <official_title>Oral Probiotics (Infloran®) for Prevention of Necrotizing Enterocolitis in Very Low Birth Weight Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wilheminenspital der Stadt Wien</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Necrotizing enterocolitis (NEC) is one of the most devastating gastrointestinal emergencies
      in preterm neonates and a leading cause of death and morbidity.

      The pathogenesis of NEC remains largely unclear, but it is widely considered as a
      multifactorial disease. Prematurity, enteral feeding, bacterial colonisation of the gut and
      intestinal ischemia have been proposed as major risk factors.

      Probiotics may prevent NEC by improving the maturity and function of the gut mucosal barrier,
      modulating the immune system, promoting colonization of the gut with beneficial organisms and
      preventing colonization by pathogens.

      A variety of clinical trials have evaluated the effect of different probiotic preparations on
      the occurrence of NEC in preterm infants. The results of recent metaanalyses suggest a
      benefit of probiotic bacteria in reducing the incidence of NEC and propose a change of
      practice.

      The aim of the study is to evaluate the efficacy of the probiotic preparation Infloran® in
      reducing the incidence of NEC after implementation in clinical routine in preterm (&lt; 34 weeks
      gestational age) very low birth weight infants compared to a historical cohort.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of NEC</measure>
    <time_frame>From birth to 37 weeks of gestational age (usually around 12 weeks)</time_frame>
    <description>NEC stages 2 or 3 according to Bell´s modified staging of NEC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of NEC</measure>
    <time_frame>From birth to 37 weeks of gestational age (usually around 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of enteral feeding with human milk or formula on the incidence of NEC after the implementation of Infloran®</measure>
    <time_frame>From birth to 37 weeks of gestational age (usually around 12 weeks)</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">463</enrollment>
  <condition>Necrotizing Enterocolitis</condition>
  <arm_group>
    <arm_group_label>Probiotics (Infloran)</arm_group_label>
    <description>Very low birth weight Infants receiving 2 capsules/d Infloran starting in the first week of life</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Very low birth weight Infants who did not receive Infloran (historical cohort)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Very low birth weight Infants (&lt;1500g birth weight)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Neonates admitted to the neonatal intensive care unit on day 1 of life

          -  Very low birth weight (&lt;1500 gram)

          -  Prematurity &lt; 34/0 weeks gestational age

          -  For group receiving probiotics: 230 infants born after the 20/Sep/2010 (i.e. date of
             introduction of Infloran in clinical routine)

          -  For control group (historical): 230 infants born before 2010

        Exclusion Criteria:

          -  Malformation of the gut (omphalocele, gastroschisis, intestinal atresia)

          -  Death before seven days of life, except due to NEC

          -  Transfer to another hospital before 37 weeks of corrected gestational age, except
             those who were transferred to a partner clinic using the same protocol for probiotic
             supplementation

          -  For group receiving probiotics: Infants who did not receive Infloran® starting in the
             first week of life or stopped before 34 weeks gestational age, except infants who
             developed NEC (reason for discontinuation of Infloran)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Repa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nadja Haiden, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical University Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margarita Thanhäuser, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilheminenspital der Stadt Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.meduniwien.ac.at</url>
    <description>Homepage Medical University Vienna</description>
  </link>
  <results_reference>
    <citation>Repa A, Thanhaeuser M, Endress D, Weber M, Kreissl A, Binder C, Berger A, Haiden N. Probiotics (Lactobacillus acidophilus and Bifidobacterium infantis) prevent NEC in VLBW infants fed breast milk but not formula [corrected]. Pediatr Res. 2015 Feb;77(2):381-8. doi: 10.1038/pr.2014.192. Epub 2014 Nov 25. Erratum in: Pediatr Res. 2016 Jan;79(1-1):124.</citation>
    <PMID>25423074</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2012</study_first_submitted>
  <study_first_submitted_qc>December 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2012</study_first_posted>
  <last_update_submitted>April 20, 2015</last_update_submitted>
  <last_update_submitted_qc>April 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Andreas Repa</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Very Low Birth Weight Infants</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Necrotizing Enterocolitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enterocolitis</mesh_term>
    <mesh_term>Enterocolitis, Necrotizing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

